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This multicenter phase II study investigated a selective radiotherapy dose increase to tumor areas with significant 18 F-misonidazole ( 18 F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC). Methods: Eligible patients had locally advanced NSCLC and no contraindication to concomitant chemoradiotherapy. The 18 F-FMISO uptake on PET/CT was assessed by trained experts. If there was no uptake, 66 Gy were delivered. In 18 F-FMISO-positive patients, the contours of the hypoxic area were transferred to the radiation oncologist. It was necessary for the radiotherapy dose to be as high as possible while fulfilling dose-limiting constraints for the spinal cord and lungs. The primary endpoint was tumor response (complete response plus partial response) at 3 mo. The secondary endpoints were toxicity, disease-free survival (DFS), and overall survival at 1 y. The target sample size was set to demonstrate a response rate of 40% or more (bilateral a 5 0.05, power 1-b 5 0.95). Results: Seventy-nine patients were preincluded, 54 were included, and 34 were 18 F-FMISO-positive, 24 of whom received escalated doses of up to 86 Gy. The response rate at 3 mo was 31 of 54 (57%; 95% confidence interval [CI] , 43%-71%) using RECIST 1.1 (17/34 responders in the 18 
F-FMISO-positive group).
Radi otherapy is a major component in the treatment of nonresectable locally advanced non-small cell lung cancer (NSCLC) (1) . Although concomitant radiochemotherapy (CCRT) is the current standard for curative-intent treatment, the tumor control rate and survival probabilities remain disappointing. Improvements in radiotherapy techniques should yield better intrathoracic control; a reduction in secondary distant dissemination; less normal-tissue damage; and as a consequence, reduced mortality caused by cancer, toxicity, or worsening of preexisting comorbidities. The identification of the adequate target volumes and the delivery of sufficiently high total doses are closely linked. Phase II studies have shown that higher doses could only be delivered to smaller target volumes (2, 3) . The RTOG 0617 randomized trial reported lower survival probabilities in the patients having received more than 60 Gy, possibly because the target volumes were too large (4) . Therefore, it is tempting to reduce the target volumes and escalate the radiotherapy dose only to the most aggressive parts of the tumor. For example, the dose could be selectively increased in the tumor areas with the highest 18 F-FDG uptake (5, 6) . Because oxygen is the most powerful radiosensitizer (7), we hypothesized that the hypoxic areas in the tumor would be relevant targets for selective dose escalation.
In a phase II study, we used 18 F-misonidazole ( 18 F-FMISO), a PET/ CT tracer for hypoxic cells, to identify and delineate hypoxic areas as biologic target volumes (BTVs) for escalated total dose radiotherapy associated with concomitant chemotherapy. A rigorous quality assurance protocol was set to ensure that all PET/CT images were acquired under reproducible conditions. The presence of 18 F-FMISO uptake was assessed by consensus by trained experts (8) . The BTVs were centrally delineated. The primary endpoint was the tumor response at 3 mo after CCRT. The secondary endpoints were acute and late toxicity, as well as disease-free survival (DFS) and overall survival (OS) at 1 y.
MATERIALS AND METHODS

Study Design and Patients
The design of the study is described in Figure 1 . Between June 6, 2012, and March 19, 2015 , the patients with NSCLC referred to the participating centers for CCRT were prospectively preincluded. Fifteen academic centers included patients into the study.
The main inclusion criteria were age older than 18 y; histologic proof of NSCLC with a measurable tumor (RECIST1.1); World Health Organization performance status of 1 or less; eligibility for curativeintent CCRT (no pleural, pulmonary, or extrathoracic metastases and no comorbidity contraindicating CCRT); adequate lung function (forced expiratory volume $ 40% and diffusing capacity of the lung (divided by the alveolar volume $ 50% of the predicted values; PaO 2 $ 60 mm Hg); a neutrophil count of more than 1.5 · 10 9 cells/L, platelet count more than 100 · 10 9 /L, and hemoglobin more than 10 g/dL; and an estimated creatinine clearance of more than 60 mL/min. All patients had to receive cisplatin-based chemotherapy as the induction treatment and concomitantly with radiotherapy. Inclusion was confirmed after completion of a radiotherapy plan confirming that the dose objective (a minimum dose of 60 Gy in 99% of the planning target volume) and the constraints (lungs, spinal cord) could be met.
The noninclusion criteria were histology other than primary NSCLC; a nonevaluable lesion (complete remission after induction chemotherapy); no uptake or metastases on the first acquisition of 18 F-FDG PET/CT ( 18 F-FDG 1 PET/CT) performed after the induction chemotherapy and before CCRT; contraindication of curative-intent radiotherapy (tumor extension, World Health Orgainziation performance status $ 2, coexistent disease); synchronous cancer or previous malignancy within 5 y before inclusion; patient already participating in another clinical trial; confirmed or suspected pregnancy and lactating females; renal insufficiency contraindicating cisplatin treatment; patients under legal protection; inability to comply with the follow-up procedures for geographic, social, or psychologic reasons; uncontrolled diabetes mellitus (blood glucose $ 10 mmol/L); and patients unable to give informed consent.
The eligible patients had to have at least 1 18 F-FDG-avid lesion at 18 F-FDG 1 PET/CT. These patients were then considered to have hypoxic lesions if significant 18 F-FMISO uptake was observed in the 18 F-FDGavid lesions on a subsequent first 18 F-FMISO performed before CCRT ( 18 F-FMISO 1 ) PET/CT scan within 8 d. The evaluable population was formed from all the eligible patients who completed the protocol (a complete mandatory dataset is included at the end of the study). The patients who eventually withdrew their consent to participate were not evaluated.
The protocol and the consent form were approved by the Comité de Protection des Personnes Nord-Ouest 1 (July 21, 2011). All patients gave their written, informed consent. The study was registered in the Clinical Trials Protocol Registration System (NCT01576796; RTEP5 study). The clinical, biologic, imaging, and toxicities data were monitored by a certified clinical research unit.
PET Imaging
The PET/CT machines were Biograph Sensation 16 (Siemens), Gemini (Philips), or Discovery LS (GE Healthcare). For each patient, 2 18 F-FDG PET/CT and 2 18 F-FMISO PET/CT scans were acquired using the same machine and under the identical operational conditions. Quality control (QC) was centrally supervised to secure homogeneity in the image quality in all participating centers. The QC procedures and results are provided in the supplemental materials (available at http://jnm.snmjournals.org).
The 18 F-FDG PET images were acquired in treatment position (arms over the head, free breathing), at least 15 d after the last administration of chemotherapy. No chemotherapy was allowed between the PET/CT and the start of radiotherapy. Six to 8 bed positions per patient were acquired from the head to the upper third of the thighs. The images were acquired at a minimum of 60 6 10 min after the 18 F-FDG injection. The patients were required to fast overnight or for at least 6 h before the imaging to ensure that the serum glucose and endogenous serum insulin levels were low at the time of the 18 F-FDG administration. The blood glucose levels were measured before each 18 F-FDG PET acquisition. A total of 4.5 MBq/kg were administered intravenously after a rest period of at least 20 min. The first acquisition ( 18 F-FDG 1 ) after the induction chemotherapy started at T 1 5 60 6 10 min after injection. The second 18 F-FDG PET ( 18 F-FDG 2 ) was performed during the fifth week of radiotherapy at a total dose of 40-46 Gy as previously demonstrated (9) . The acquisition procedure followed conditions identical to those for 18 F-FDG 1 , specifically, with a T2 5 T1 6 5 min.
The 18 F-FMISO PET images were acquired under identical conditions. Two to 3 bed positions per patient were acquired for the thorax. The images were acquired at a minimum of 240 6 20 min after the 18 F-FMISO injection. A total of 4.5 MBq/kg were administered intravenously after For all the 18 F-FDG and 18 F-FMISO acquisitions, the CT scan data were used for random coincidences, scatter and attenuation correction, and anatomic localization. The PET images ( 18 F-FDG and 18 F-FMISO) were fused with the CT scan images. The 18 F-FMISO PET images were finally smoothed with a gaussian filter (full width at half maximum, 5 mm).
PET Analysis
We previously showed (8) that the assessment of 18 F-FMISO/ 18 F-FDG uptake (presence vs. absence) was reproducible in a multicenter setting. In this study, 3 independent experts (of 9) reviewed the 18 F-FMISO PET acquisitions and decided on the presence or absence of uptake within 48 h.
Because the interobserver agreement for the 18 F-FMISO volume measurements was low (8) In addition, the 18 F-FDG and 18 F-FMISO images on PET after the induction chemotherapy (PET 1 ) and during radiotherapy (PET 2 at 40-46 Gy) were used to calculate the maximum SUVs (PET SUVmax1 and PET SUVmax2 )-that is, the highest-activity pixel value in the BTVsand the percentages of variation in SUV max (D%SUV max ) and BTV (D%BTV). The SUV mean yielded results similar to those of the SUV max and are not presented here.
Radiochemotherapy Protocol
The microscopic extension around the BTV m (clinical target volume [CTV]) was obtained either by isotropic expansion around the tumor (6 mm for squamous cell carcinoma, 8 mm for adenocarcinoma) (11) or by delineation of the 18 F-FDG PET/CT-positive mediastinal nodes (12) . The isotropic CTV margin around the BTV h was set to 5 mm. The margin for the planning target volume (PTV) was 10 mm around the CTV (possibly 15 mm in the craniocaudal direction) to take into account internal movements and uncertainties in positioning.
All the dose calculations were corrected for heterogeneity. Intensity-modulated radiotherapy (IMRT) was not allowed. The total dose was prescribed by the International Commission for Radiation Units point. The dose delivered in the PTV had to be within 95% and 107% of the prescribed dose. The target total dose was 86 Gy, provided that the maximum dose to the spinal cord was strictly less than 46 Gy and that no more than 30% of the total lung volume (excluding the gross tumor volume) received more than 20 Gy. As minor constraints, no more than 30% of the esophagus or the heart could receive more than 50 or 35 Gy, respectively. 
Follow-up Procedures
The efficacy and toxicity assessments were planned at 3 mo and 1 y after the end of treatment (clinical examination, CT scanner).
Endpoints
The primary endpoint was the tumor response on CT scan at 3 mo (RECIST 1.1). Complete response (CR) was defined as no residual tumor image. Partial response (PR) was defined as a more than 30% reduction in maximal diameter. Progressive disease was defined as a more than 20% increase in the maximal diameter, whereas variations between 230% and 120% were classified as stable disease. The secondary endpoints were early and late toxicity (Common Terminology Criteria for Adverse Events) as well as DFS and OS at 1 y from definitive inclusion.
Sample Size
This open-label, single-arm, nonrandomized, multicenter phase II study followed a Gehan 2-step design. In the first step, 6 patients had to be evaluable 3 mo after completion of treatment. If no CR or PR The number of patients to include was calculated as follows to obtain 25 patients evaluable at 3 mo (and 15 patients alive at 1 y, a 50% OS probability). Assuming 5 deaths/ lost for follow-up at 3 mo, 30 patients with hypoxic lesions should be recruited and receive CCRT. Assuming that 50% of 18 F-FMISO 1 PET/CT would demonstrate the presence of hypoxic lesions, 60 preincluded patients should have persistent 18 F-FDG uptake on the postinduction chemotherapy 18 F-FDG 1 PET/CT. We anticipated that 20% of the patients would have a negative 18 F-FDG 1 PET/ CT result after induction chemotherapy (9) . Therefore, a total of 75 patients would have to be preincluded. The 30 patients without 18 F-FMISO-avid lesions would be monitored for 1 y (a secondary endpoint).
Statistical Analysis
All analyses were conducted according to intent to treat, for example, irrespective of the radiotherapy total dose that was actually delivered. Descriptive statistics (n, mean, SD minimum and maximum) were calculated for the quantitative variables. Frequency and percentages with 95% confidence intervals (CIs) were determined for the qualitative variables. A Levene test was used to assess the equality of variances before comparing the quantitative variables between 2 or more groups (ANOVA). The survival probabilities were compared with a log-rank test. All the significance thresholds were set at 0.05 (2-tailed test). All the statistics were performed using SPSS software (version 20.0; IBM).
RESULTS
Patient Characteristics, Flowchart, and Descriptive Results
The study flow is shown in Figure 1 . Seventy-nine patients were preincluded, and 54 patients were definitely included. The reasons for noninclusion were as follows: 8 inadequate procedures, 9 metastases and 3 with an absence of uptake on the 18 F-FDG 1 PET/CT, 4 consent withdrawals, and 1 investigator's decision. Thirty-four patients were eligible for the experimental group ( 18 F-FDG 1 -positive and 18 F-FMISO 1 -positive).
The 54 definitively included patients were predominantly men (7 women and 47 men), with a mean age 6 SD of 60.3 6 7.7 y ( Table  1 ). The histologic subtypes were 26 (48%) squamous cell carcinomas, 21 (39%) adenocarcinomas, and 7 (13%) undifferentiated carcinomas. The disease stages were mostly IIIA and IIIB. The descriptive data of the 79 preincluded patients were not significantly different (data not shown).
In the experimental arm, 24 of 34 (71%) patients received increased radiotherapy total doses (86 Gy, 5 patients; 80 Gy, 2; 76 Gy, 8; 74 Gy, 5, 72 Gy, 2; 70 Gy, 2). Because of organ-at-risk constraints, the dose was limited to 66 Gy in 10 patients. Among the 20 patients without 18 F-FMISO uptake, 19 received 66 Gy, and 1 received 68 Gy.
PET Description
The PET data are reported in Table 2 . For the 54 included patients, the 54 18 F-FDG 1 and 54 18 F-FMISO 1 were available before the CCRT. In the 34 of 54 patients with hypoxia, 32 of 34 18 F-FDG 2 , and 31 of 34 18 F-FMISO 2 could be performed during the CCRT at 42 Gy (missing PETs because of medical or technical problems). The mean time intervals between injection and imaging were 66 (SD 5 10) and 236 (SD 5 6) min for the 18 F-FDG and 18 F-FMISO PET/CT, respectively. A total of 103 lesions (40 primary tumors and 63 nodes) were observed in the 54 patients. The per-patient and perlesion analyses gave similar results. We present only per-patient PET data.
The patients with hypoxic lesions had significantly higher 18 F-MISO 1 SUV max than the patients without hypoxia (P , 0.001). Similarly, the patients with hypoxia had higher 18 F-FDG SUV max1 (P 5 0.02) and larger 18 F-FDG BTV1 tumor volumes (P 5 0.03). The BTVs delineated on PET after the induction chemotherapy were approximately 40% smaller with 18 F-FMISO than with 18 F-FDG (SD = 54%), without statistically significant differences between the radiotherapy dose groups. For the 34 hypoxic patients who underwent 18 F-FDG (n 5 32) and 18 F-FMISO (n 5 31) during CCRT, 18 F-FDG SUV max , 18 F-FDG BTV , and 18 F-FMISO SUV max significantly decreased during CCRT.
Toxicity
Acute and late toxicities are listed in Tables 3 and 4 , respectively. There was 1 grade 4 acute pneumonitis case among the 24 patients who received escalated radiotherapy doses. Three acute grade 4 toxicities were observed in the patients having received 66 Gy (whatever their 18 F-FMISO uptake). One death (hemoptysis) occurred before the evaluation at 3 mo among the 10 patients with 18 F-FMISO uptake and having received 66 Gy. No grade 4 or 5 late radiotherapyrelated adverse events or acute/late cardiac toxicities were reported in the entire population. The causes of the 19 reported deaths are described below.
Tumor Response and Survival
The survival curves are presented in Figure 2 . The tumor response was evaluated at 3 mo (67 d). The patient who died before evaluation at 3 mo in the 18 F-FMISO-positive/66-Gy group was considered as having a nonresponding tumor. The response (CR1PR) rate at 3 mo was 31 of 54 (57% with 95% CI, 43%-71%). The corresponding figures were 17 of 34 (50%; 95% CI, 34%-66%) in the patients with 18 F-FMISO uptake versus 14 of 20 (70%; 95% CI, 48%-85% in the patients without uptake (P 5 0.25). In the 18 F-FMISO-positive patients, the response rates were 12 of 24 (50%; 95% CI, 31%-69%) after the escalated radiotherapy doses and 5 of 10 (50%; 95% CI, 24%-76%) after 66 Gy.
At the date of point, 35 patients were alive (a median follow-up duration of 14 mo [range 5-21 mo]), and 19 were alive without disease (15 mo [range, 11-21 mo] ). Sixteen of the 19 deaths were due to cancer (9/10 in the high-radiotherapy-dose group, 3/4 in the 18 F-FMISO-positive group, and 4/5 in the 18 F-FMISO-negative group). The patient in the 18 F-FMISO-positive/66-Gy group who died at 3 mo was discussed above. One patient in the high-radiotherapydose group was receiving nivolumab for progression under pemetrexed/ bevacizumab maintenance. He died at home 17 mo after inclusion, and the cause of death remains unknown (drug toxicity or tumor progression). One patient in the 18 F-FMISO group, without previous documentation of a relapse, was admitted to a palliative care unit with cognitive impairment, fever, and intestinal bleeding. He refused investigations and died at 18 mo. The OS and DFS probabilities at 1 y for the entire group were 0.86 (95% CI, 0.77-0.96) and 0. P 5 0.02). In the 18 F-FMISO-positive patients, the DFS was similar regardless of whether the radiotherapy dose was 66 Gy (0.50 [95% CI, 0.18-0.75]) or higher (0.50 [95% CI, 0.29-0.68]).
DISCUSSION
Our purpose was to increase the total dose of radiotherapy in the hypoxic parts of NSCLC in patients who were candidates for curative-intent chemoradiotherapy. Hypoxia has been shown to strongly reduce the radiosensitivity of tumor cells and to be associated with local failure (7) . In this study, a key issue was to timely provide the radiation oncologists with a reliable target, anatomically and functionally defined, in a prospective multicenter setting. We have demonstrated that hypoxic areas were identified using 18 F-FMISO PET in 34 of 54 patients (15 centers) and that higher radiotherapy doses (70-86 Gy) could be delivered without excessive toxicity in 24 patients with hypoxic areas. There were no statistically significant differences in the tumor response rates at 3 mo, and the OS at 1 y was similar among the 3 treatment groups. The DFS probability was significantly lower in the 18 F-FMISO-positive patients, regardless of the radiotherapy dose. To our knowledge, we present the largest series of patients with NSCLC receiving radiotherapy boosted based on the hypoxia PET/CT in multicentric and prospective conditions.
As a targeted treatment, radiotherapy critically depends on accurate delineation of the volumes to be irradiated. A conventional CT scan is necessary for planning (Hounsfield units being correlated to electronic densities) and for drawing the anatomic contours of the tumor and the organs at risk. As for functional information (e.g., glucose metabolism with 18 F-FDG), the PET/CT images must be either acquired in the treatment position or registered onto the planning CT. 18 F-FMISO is one of several tracers that accumulate in hypoxic areas (13) and was selected for this study because it is commercially available. Although this study was ongoing, the MAASTRO group demonstrated (using HX4) that hypoxia images were stable when PET/CT was repeated (14) and provided a representation of the tumor functional status that was different from 18 F-FDG images (15) . A planning study of 10 patients by the same group showed that hypoxia images could be used to consider delivering heterogeneous doses to the tumor, specifically higher doses to hypoxic areas (16) . All the PET tracers of hypoxia yield a relatively low signal-tonoise ratio. Therefore, the initial step of this study was to validate a reproducible method to identify the tumors with hypoxic areas and delineate BTVs for radiotherapy (8) . The patients with hypoxia were identified by at least 3 trained experts, and the delineation of all the BTVs was centralized in 1 center. An example of 18 F-FDG and 18 F-FMISO images with BTV are presented in Figure 3 .
We did not gate our PET acquisitions on breathing movements. Because 18 F-FMISO uptake is known to be low in lung tumors (SUV max 5 2.5 [60.7] in our study), good-quality images cannot be obtained in respiratory gated mode, either for SUV measurement or for BTV h delineation. Our criteria for BTV h delineation was validated in free-breathing patients. We chose not to add further complexity to our design by requiring gated PET acquisitions and, for the sake of consistency, irradiations. In addition, mobile tumors are usually small and located in the parenchyma whereas most stage III tumors are large (and take up 18 F-FMISO) and involve the mediastinum, that is, are mostly fixed. Lin et al. (17) have suggested a low reproducibility of 18 F-FMISO PET images performed within 48 h. More recently, a preclinical study by Busk et al. (18) showed a good reproducibility of PET FAZA images acquired within 48 h (r 5 0.82; range, 0.72-0.90), and Zegers et al. demonstrated the reproducibility of PET HX4 images in a human study (14) . Mathematic simulations based on microscopic tumor tissue sections compared 18 F-FMISO, FAZA, and HX4 and showed that 18 F-FMISO provides a robust and reproducible signal 4 h after injection, with a lower contrast (19) . Our observation that 18 F-FMISO-avid tumors have a much worse prognosis confirms that hypoxia imaged on a single PET acquisition is a strong prognostic indicator, making it a relevant target volume for selective radiotherapy dose increase.
Radiobiologic and clinical data (7) suggest that total doses above 80 Gy are required to achieve tumor control in NSCLC. The RTOG 0617 (4) randomized trial reported reduced OS probabilities in patients receiving 74 Gy (vs. 60 Gy) in a target volume (median, 90 cc) defined on 18 An extensive discussion about radiotherapy dose and delivery is beyond the scope of the present paper. Briefly, our patients were irradiated with a 3-dimensional conformal technique. When our trial was designed, IMRT was available in too few French centers. IMRT was used in approximately 50% of the RTOG 0617 patients with outcomes similar to 3-dimensional RT (4). The dosimetry benefits of IMRT have not been confirmed in a randomized trial (20) . The dosimetry of protons is characterized by localized high-dose delivery and sharp fall-out (Bragg peak) (21) . No significant differences in tumor outcome were observed in a randomized comparison of 3-dimensional proton therapy versus IMRT (22) . Radiotherapy in stereotactic conditions is an accepted treatment for tumors up to 65 cc, provided that strict organ at risk dose-volume constraints are met (23) . Our patients had mean 18 F-FMISO-avid volumes of 33.5 cc, with large variability (SD = 52.2 cc; range, 1-234 cc). A few additional fractions could be delivered, intended as a concomitant boost, whereas the 18 F-FDG-defined target volume is be treated conventionally (2 Gy per fraction), keeping the treatment duration around 6-7 wk. The positive results of accelerated radiotherapy (24) suggest that tumor proliferation during radiotherapy might have contributed to the failure of escalated radiotherapy dosage delivered over a protracted treatment time to improve the outcome in NSCLC (4) .
CONCLUSION
This prospective phase II study demonstrates the feasibility of delivering higher radiotherapy doses to smaller target volumes identified by 18 F-FMISO uptake without exceeding the tolerance to the normal organs. The benefit of this approach, possibly with larger doses per fraction in stereotactic conditions as a concomitant boost, remains to be investigated in a randomized trial.
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